09. 11(Thu)
09. 11(Thu) 16:20~17:50 Room 2
Familial Hypercholesterolemia (FH) in the Era of Precision Medicine
09. 12(Fri)
09. 12(Fri) 08:30~10:00 Room 2
Comprehensive Strategies for the Prevention of Atherosclerosis: Current Insights and Future Directions
- Inflammation and atherosclerosis: emerging biomarkers and anti-inflammatory therapies 08:30~08:50
- The role of digital health technology in managing atherosclerosis: a new frontier 08:50~09:10
- Impact of lipid-lowering therapy on aortic aneurysm progression and cardiovascular outcomes 09:10~09:30
- Panel Discussion 09:30~10:00
09. 12(Fri) 16:45~18:15 Room 2
Lipid-Lowering Strategies: Targets and Therapies in Clinical Practice
- Triglyceride and HDL-C focus in Asian populations: rethinking priorities? 16:45~17:05
- Combination lipid-lowering therapy: when statins alone are not enough 17:05~17:25
- Ethnic differences in managing dyslipidemia: tailoring treatment strategies for Asian and Western populations 17:25~17:45
- Panel Discussion 17:45~18:15
09. 13(Sat)
09. 13(Sat) 08:50~10:20 Room 2
Long-term Exposure to LDL-cholesterol and Early Cardiovascular Risk Prevention
09. 13(Sat) 14:50~16:20 Room 2
Role of Medicinal Foods in Atherosclerosis and Cardiometabolic Disease
09. 13(Sat) 16:20~17:50 Room 2
The Impact of Remnant Cholesterol on Various Disease Pathologies and Clinical Outcomes
- Remnant cholesterol as a key contributor to atherosclerotic cardiovascular disease (ASCVD): mechanisms and clinical implications 16:20~16:35
- The role of remnant cholesterol in chronic kidney disease (CKD) progression and cardiovascular risk 16:35~16:50
- Association between remnant cholesterol and dementia: potential mechanisms and clinical perspectives 16:50~17:05
- Remnant cholesterol in women’s cardiometabolic health 17:05~17:20
- Panel Discussion 17:20~17:50
09. 13(Sat) 16:20~17:50 Room 4
Recent Evidence in Non-invasive Cardiovascular Risk Assessment Techniques
